Comparison of the bronchodilating effects of SCH 1000 with isoproterenol in patients with bronchial asthma

T. Vlagopoulos, R. G. Townley, S. Ghazanshahi, Againdra K. Bewtra, K. Burke

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The effect of SCH 1000 and isoproterenol was evaluated in 10 patients with extrinsic asthma. The onset of action for the SCH 1000 dose compared to the baseline response occurred at or before 15 minutes (FEV 1 and MEFR). The onset of action for the isoproterenol dose occurred at or before one minute for all three pulmonary function variables. At the 1, 3, 6 and 15 minute intervals the response to the isoproterenol dose was significantly greater than the response to the SCH 1000 dose for FEV 1, FVC and MEFR. At 30 and 60 minutes, however, the response to SCH 1000 was progressively increasing, whereas the response to isoproterenol was decreasing. The maximum improvement in FEV 1 for isoproterenol was 49% at three and six minutes, whereas for SCH 1000 was 28% at 60 minutes. In patients with chronic bronchitis or bronchial asthma SCH 1000 may be considered as a therapeutic alternative to beta adrenergic bronchodilators and in patients who also have cardiac arrhythmias or angina pectoris and are adversely affected by sympathomimetic drugs.

Original languageEnglish
Pages (from-to)223-230
Number of pages8
JournalAnnals of Allergy
Volume36
Issue number4
StatePublished - 1976
Externally publishedYes

Fingerprint

Isoproterenol
Asthma
Maximal Expiratory Flow Rate
Sympathomimetics
Bronchodilator Agents
Chronic Bronchitis
Angina Pectoris
Adrenergic Agents
Cardiac Arrhythmias
Lung
Therapeutics

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy

Cite this

Comparison of the bronchodilating effects of SCH 1000 with isoproterenol in patients with bronchial asthma. / Vlagopoulos, T.; Townley, R. G.; Ghazanshahi, S.; Bewtra, Againdra K.; Burke, K.

In: Annals of Allergy, Vol. 36, No. 4, 1976, p. 223-230.

Research output: Contribution to journalArticle

Vlagopoulos, T, Townley, RG, Ghazanshahi, S, Bewtra, AK & Burke, K 1976, 'Comparison of the bronchodilating effects of SCH 1000 with isoproterenol in patients with bronchial asthma', Annals of Allergy, vol. 36, no. 4, pp. 223-230.
Vlagopoulos, T. ; Townley, R. G. ; Ghazanshahi, S. ; Bewtra, Againdra K. ; Burke, K. / Comparison of the bronchodilating effects of SCH 1000 with isoproterenol in patients with bronchial asthma. In: Annals of Allergy. 1976 ; Vol. 36, No. 4. pp. 223-230.
@article{6f6ab7962f784dd191ff2e513ff47ab5,
title = "Comparison of the bronchodilating effects of SCH 1000 with isoproterenol in patients with bronchial asthma",
abstract = "The effect of SCH 1000 and isoproterenol was evaluated in 10 patients with extrinsic asthma. The onset of action for the SCH 1000 dose compared to the baseline response occurred at or before 15 minutes (FEV 1 and MEFR). The onset of action for the isoproterenol dose occurred at or before one minute for all three pulmonary function variables. At the 1, 3, 6 and 15 minute intervals the response to the isoproterenol dose was significantly greater than the response to the SCH 1000 dose for FEV 1, FVC and MEFR. At 30 and 60 minutes, however, the response to SCH 1000 was progressively increasing, whereas the response to isoproterenol was decreasing. The maximum improvement in FEV 1 for isoproterenol was 49{\%} at three and six minutes, whereas for SCH 1000 was 28{\%} at 60 minutes. In patients with chronic bronchitis or bronchial asthma SCH 1000 may be considered as a therapeutic alternative to beta adrenergic bronchodilators and in patients who also have cardiac arrhythmias or angina pectoris and are adversely affected by sympathomimetic drugs.",
author = "T. Vlagopoulos and Townley, {R. G.} and S. Ghazanshahi and Bewtra, {Againdra K.} and K. Burke",
year = "1976",
language = "English",
volume = "36",
pages = "223--230",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "4",

}

TY - JOUR

T1 - Comparison of the bronchodilating effects of SCH 1000 with isoproterenol in patients with bronchial asthma

AU - Vlagopoulos, T.

AU - Townley, R. G.

AU - Ghazanshahi, S.

AU - Bewtra, Againdra K.

AU - Burke, K.

PY - 1976

Y1 - 1976

N2 - The effect of SCH 1000 and isoproterenol was evaluated in 10 patients with extrinsic asthma. The onset of action for the SCH 1000 dose compared to the baseline response occurred at or before 15 minutes (FEV 1 and MEFR). The onset of action for the isoproterenol dose occurred at or before one minute for all three pulmonary function variables. At the 1, 3, 6 and 15 minute intervals the response to the isoproterenol dose was significantly greater than the response to the SCH 1000 dose for FEV 1, FVC and MEFR. At 30 and 60 minutes, however, the response to SCH 1000 was progressively increasing, whereas the response to isoproterenol was decreasing. The maximum improvement in FEV 1 for isoproterenol was 49% at three and six minutes, whereas for SCH 1000 was 28% at 60 minutes. In patients with chronic bronchitis or bronchial asthma SCH 1000 may be considered as a therapeutic alternative to beta adrenergic bronchodilators and in patients who also have cardiac arrhythmias or angina pectoris and are adversely affected by sympathomimetic drugs.

AB - The effect of SCH 1000 and isoproterenol was evaluated in 10 patients with extrinsic asthma. The onset of action for the SCH 1000 dose compared to the baseline response occurred at or before 15 minutes (FEV 1 and MEFR). The onset of action for the isoproterenol dose occurred at or before one minute for all three pulmonary function variables. At the 1, 3, 6 and 15 minute intervals the response to the isoproterenol dose was significantly greater than the response to the SCH 1000 dose for FEV 1, FVC and MEFR. At 30 and 60 minutes, however, the response to SCH 1000 was progressively increasing, whereas the response to isoproterenol was decreasing. The maximum improvement in FEV 1 for isoproterenol was 49% at three and six minutes, whereas for SCH 1000 was 28% at 60 minutes. In patients with chronic bronchitis or bronchial asthma SCH 1000 may be considered as a therapeutic alternative to beta adrenergic bronchodilators and in patients who also have cardiac arrhythmias or angina pectoris and are adversely affected by sympathomimetic drugs.

UR - http://www.scopus.com/inward/record.url?scp=0017289875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017289875&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - 223

EP - 230

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 4

ER -